[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-metastatic-nasopharyngeal-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-metastatic-nasopharyngeal-carcinoma":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":5},"100597745",false,"NCT07062484","A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. age of at least 18 years;\n2. Karnofsky Performance Status (KPS) ≥60;\n3. histologically confirmed nasopharyngeal squamous carcinoma;\n4. metastatic disease after primary standard treatment (patients who had metastatic diseases over six months after treatment);\n5. at least 1 measurable metastatic lesions in lung or mediastinal or pleura (imaging for distant metastases with FDG-PET\u002FCT or chest\u002Fabdomen CT with contrast);\n6. adequate renal , liver and bone marrow function.\n\nExclusion Criteria:\n\n1. previous treatment with an immune checkpoint inhibitor;\n2. recurrent disease;\n3. previous systemic chemotherapy for metastatic disease;\n4. symptomatic central nervous system metastases;\n5. a history of non-infectious pneumonitis that required glucocorticoids, or active autoimmune disease;\n6. severe organ dysfunction or not suitable for chemoradiotherapy;\n7. individuals that had serious kidney, heart, blood, nervous system, or liver diseases or psychiatric disorders;\n8. individuals that had taken part in any other clinical trials testing other drugs within 3 months of the present study;\n9. other patients whom researchers deemed unsuitable to participate in the study.","ALL","18 Years",{"count":17,"type":18},600,"ESTIMATED","INTERVENTIONAL",[21],"NA","This study is a retrospective real-world study. In this study, we plan to collect the clinical data of lung metastatic nasopharyngeal carcinoma patients who received PD-1 inhibitors and chemotherapy combined with or without radiotherapy.",[24],"Lung Metastatic Nasopharyngeal Carcinoma","NOT_YET_RECRUITING","2025-07-10",{"date":28,"type":29},"2025-07-14","ACTUAL",{"date":31,"type":18},"2025-07",{"date":33,"type":18},"2025-12",{"name":35,"class":36},"Sichuan Cancer Hospital and Research Institute","OTHER",""]